Maureen A. Shaw
Cincinnati Children's Hospital Medical Center
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Maureen A. Shaw.
Cancer Research | 2010
Kris A. Steinbrecher; Netanel A. Horowitz; Elizabeth A. Blevins; Kelley A. Barney; Maureen A. Shaw; Eleana Harmel-Laws; Fred D. Finkelman; Matthew J. Flick; Malinda D. Pinkerton; Kathryn E. Talmage; Keith W. Kombrinck; David P. Witte; Joseph S. Palumbo
A link between colitis and colon cancer is well established, but the mechanisms regulating inflammation in this context are not fully defined. Given substantial evidence that hemostatic system components are powerful modulators of both inflammation and tumor progression, we used gene-targeted mice to directly test the hypothesis that the coagulation factor fibrinogen contributes to colitis-associated colon cancer in mice. This fundamental provisional matrix protein was found to be an important determinant of colon cancer. Fibrinogen deficiency resulted in a dramatic diminution in the number of colonic adenomas formed following azoxymethane/dextran sodium sulfate challenge. More detailed analyses in mice expressing a mutant form of fibrinogen that retains clotting function, but lacks the leukocyte integrin receptor alpha(M)beta(2) binding motif (Fibgamma(390-396A)), revealed that alpha(M)beta(2)-mediated engagement of fibrin(ogen) is mechanistically coupled to local inflammatory processes (e.g., interleukin-6 elaboration) and epithelial alterations that contribute to adenoma formation. Consistent with these findings, the majority of Fibgamma(390-396A) mice developed no discernable adenomas, whereas penetrance was 100% in controls. Furthermore, the adenomas harvested from Fibgamma(390-396A) mice were significantly smaller than those from control mice and less proliferative based on quantitative analyses of mitotic indices, suggesting an additional role for fibrin(ogen) in the growth of established adenomas. These studies show, for the first time, a unique link between fibrin(ogen) and the development of inflammation-driven malignancy. Given the importance of antecedent inflammation in the progression of numerous cancers, these studies suggest that therapies targeting fibrin(ogen)-alpha(M)beta(2) interactions may be useful in preventing and/or treating this important subset of malignancies.
Blood | 2009
Eric S. Mullins; Keith W. Kombrinck; Kathryn E. Talmage; Maureen A. Shaw; David P. Witte; Joni M. Ullman; Sandra J. Friezner Degen; William Sun; Matthew J. Flick; Jay L. Degen
Mice carrying a conditional prothrombin knockout allele (fII(lox)) were established to develop an experimental setting for exploring the importance of thrombin in the maintenance of vascular integrity, the inflammatory response, and disease processes in adult animals. In the absence of Cre-mediated recombination, homozygous fII(lox/lox) mice or compound heterozygous mice carrying one fII(lox) allele and one constitutive-null allele were viable. Young adults exhibited neither spontaneous bleeding events nor diminished reproductive success. However, the induction of Cre recombinase in fII(lox) mice using the poly I:C-inducible Mx1-Cre system resulted in the rapid and near-complete recombination of the fII(lox) allele within the liver, the loss of circulating prothrombin, and profound derangements in coagulation function. Consistent with the notion that thrombin regulates coagulation and inflammatory pathways, an additional early consequence of reducing prothrombin was impaired antimicrobial function in mice challenged with Staphylococcus aureus peritonitis. However, life expectancy in unchallenged adults genetically depleted of prothrombin was very short ( approximately 5-7 days). The loss of viability was associated with the development of severe hemorrhagic events within multiple tissues, particularly in the heart and brain. Unlike the constitutive loss of either clotting or platelet function alone, the conditional loss of prothrombin is uniformly not compatible with maintenance of hemostasis or long-term survival.
Biomacromolecules | 2014
Yongshun Huang; Maureen A. Shaw; Eric S. Mullins; Terence L. Kirley; Neil Ayres
Polyurea-based synthetic glycopolymers containing sulfated glucose, mannose, glucosamine, or lactose as pendant groups have been synthesized by step-growth polymerization of hexamethylene diisocyanate and corresponding secondary diamines. The obtained polymers were characterized by gel permeation chromatography, nuclear magnetic resonance spectroscopy, and Fourier transform infrared spectroscopy. The nonsulfated polymers showed similar results to the commercially available biomaterial polyurethane TECOFLEX in a platelet adhesion assay. The average degree of sulfation after reaction with SO3 was calculated from elemental analysis and found to be between three and four −OSO3 groups per saccharide. The blood-compatibility of the synthetic polymers was measured using activated partial thromboplastin time, prothrombin time, thrombin time, anti-IIa, and anti-Xa assays. Activated partial thromboplastin time, prothrombin time, and thrombin time results indicated that the mannose and lactose based polymers had the highest anticoagulant activities among all the sulfated polymers. The mechanism of action of the polymers appears to be mediated via an anti-IIa pathway rather than an anti-Xa pathway.
Polymer Chemistry | 2016
Yongshun Huang; Maureen A. Shaw; Mary R. Warmin; E. S. Mullins; Neil Ayres
The influence of polymer chemical structure and degree of sulfation of polyurea glycopolymers on blood compatibility is reported. Polymers were prepared using lactose-containing diamines with either toluene 2,4-diisocyanate (TDI), isophorone diisocyanate (IPDI), methylene bis(4-cyclohexyl isocyanate) (HMDI), or hexamethylene diisocyanate (HDI) and subsequntly sulfated with a sulfur trioxide reagent. The influence of degree of sulfation was investigated using a polymer. Polyurea glycopolymers with sulfur contents ranging from ∼3% to 15% were prepared from HMDI polymerized with the lactose-containing diamine. The obtained glycopolymers have been characterized using gel permeation chromatography, nuclear magnetic resonance spectroscopy, Fourier transform infrared spectroscopy, and elemental analysis. The blood compatibility of the polymers was determined by measuring the activated partial thromboplastin time, thrombin time, and prothrombin time. Poly(HMDI-sL) exhibited higher prolongation of the activated partial thromboplastin time than other diisocyanate-containing sulfated glycopolymers, and higher degrees of sulfation result in prolonged clotting times. The polymers ability bind thrombin in the presence and absence of antithrombin III was measured using a coloremtric thrombin inhibition assay and the results followed the trend observed in the activated partial thromboplastin time assay.
The Journal of Neuroscience | 2017
Maureen A. Shaw; Zhen Gao; Kathryn E. McElhinney; Sherry Thornton; Matthew J. Flick; Adam Lane; Jay L. Degen; Jae Kyu Ryu; Katerina Akassoglou; Eric S. Mullins
Multiple sclerosis (MS) is a neuroinflammatory, demyelinating disease of the CNS. Fibrinogen deposition at sites of blood–brain barrier breakdown is a prominent feature of neuroinflammatory disease and contributes to disease severity. Plasminogen, the primary fibrinolytic enzyme, also modifies inflammatory processes. We used a murine model of MS, experimental autoimmune encephalomyelitis (EAE), to evaluate the hypothesis that the loss of plasminogen would exacerbate neuroinflammatory disease. However, contrary to initial expectations, EAE-challenged plasminogen-deficient (Plg−) mice developed significantly delayed disease onset and reduced disease severity compared with wild-type (Plg+) mice. Similarly, pharmacologic inhibition of plasmin activation with tranexamic acid also delayed disease onset. The T-cell response to immunization was similar between genotypes, suggesting that the contribution of plasminogen was downstream of the T-cell response. Spinal cords from EAE-challenged Plg− mice demonstrated significantly decreased demyelination and microglial/macrophage accumulation compared with Plg+ mice. Although fibrinogen-deficient mice or mice with combined deficiencies of plasminogen and fibrinogen had decreased EAE severity, they did not exhibit the delay in EAE disease onset, as seen in mice with plasminogen deficiency alone. Together, these data suggest that plasminogen and plasmin-mediated fibrinolysis is a key modifier of the onset of neuroinflammatory demyelination. SIGNIFICANCE STATEMENT Multiple sclerosis is a severe, chronic, demyelinating disease. Understanding the pathobiology related to the autoreactive T-cell and microglial/macrophage demyelinating response is critical to effectively target therapeutics. We describe for the first time that deficiency of plasminogen, the key fibrinolytic enzyme, delays disease onset and protects from the development of the paralysis associated with a murine model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE). Administration of a widely used, pharmacologic inhibitor of plasminogen activation, tranexamic acid, also delays the onset of neuroinflammation associated with EAE.
Blood | 2016
Maureen A. Shaw; Keith W. Kombrinck; Kathryn E. McElhinney; David R. Sweet; Matthew J. Flick; Joseph S. Palumbo; Mei Cheng; Naomi L. Esmon; Charles T. Esmon; Alexander Brill; Denisa D. Wagner; Jay L. Degen; Eric S. Mullins
Thrombin-mediated proteolysis is central to hemostatic function but also plays a prominent role in multiple disease processes. The proteolytic conversion of fII to α-thrombin (fIIa) by the prothrombinase complex occurs through 2 parallel pathways: (1) the inactive intermediate, prethrombin; or (2) the proteolytically active intermediate, meizothrombin (fIIa(MZ)). FIIa(MZ) has distinct catalytic properties relative to fIIa, including diminished fibrinogen cleavage and increased protein C activation. Thus, fII activation may differentially influence hemostasis and disease depending on the pathway of activation. To determine the in vivo physiologic and pathologic consequences of restricting thrombin generation to fIIa(MZ), mutations were introduced into the endogenous fII gene, resulting in expression of prothrombin carrying 3 amino acid substitutions (R157A, R268A, and K281A) to limit activation events to yield only fIIa(MZ) Homozygous fII(MZ) mice are viable, express fII levels comparable with fII(WT) mice, and have reproductive success. Although in vitro studies revealed delayed generation of fIIa(MZ) enzyme activity, platelet aggregation by fII(MZ) is similar to fII(WT) Consistent with prior analyses of human fIIa(MZ), significant prolongation of clotting times was observed for fII(MZ) plasma. Adult fII(MZ) animals displayed significantly compromised hemostasis in tail bleeding assays, but did not demonstrate overt bleeding. More notably, fII(MZ) mice had 2 significant phenotypic advantages over fII(WT) animals: protection from occlusive thrombosis after arterial injury and markedly diminished metastatic potential in a setting of experimental tumor metastasis to the lung. Thus, these novel animals will provide a valuable tool to assess the role of both fIIa and fIIa(MZ) in vivo.
Blood | 2015
Paritha Arumugam; Eric S. Mullins; Shiva Kumar Shanmukhappa; Brett P. Monia; Anastacia Loberg; Maureen A. Shaw; Tilat A. Rizvi; Janaka Wansapura; Jay L. Degen; Punam Malik
Blood | 2012
Eric S. Mullins; Maureen A. Shaw; Kathryn E. McElhinney; Keith W. Kombrinck; Matthew J. Flick; Alexander Brill; Denisa D. Wagner; Jay L. Degen
Polymer Chemistry | 2016
Yongshun Huang; Maureen A. Shaw; Mary R. Warmin; E. S. Mullins; Neil Ayres
Blood | 2016
Maureen A. Shaw; Zhen Gao; Eric S. Mullins